Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis.

Chen D, Xu F, Lu Y, Xia W, Du C, Xiong D, Song D, Shi Y, Yuan Z, Zheng Q, Jiang K, An X, Xue C, Huang J, Bi X, Chen M, Zhang J, Wang S, Hong R

Open source

DOI: 10.1038/s41523-024-00646-2
Published: 2024 Jun 13
Container: NPJ breast cancer
Publisher: Not recorded
Open access: yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

cautionDOI registered: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
cautionDOI resolves: No matching Crossref record was present in this response. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
supportingOpen access status: Normalized open-access status: open. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1038/s41523-024-00646-2,
  title = {Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis.},
  author = {Chen D and Xu F and Lu Y and Xia W and Du C and Xiong D and Song D and Shi Y and Yuan Z and Zheng Q and Jiang K and An X and Xue C and Huang J and Bi X and Chen M and Zhang J and Wang S and Hong R},
  year = {2024},
  journal = {NPJ breast cancer},
  doi = {10.1038/s41523-024-00646-2},
  url = {https://doi.org/10.1038/s41523-024-00646-2}
}

RIS

TY  - JOUR
TI  - Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis.
AU  - Chen D
AU  - Xu F
AU  - Lu Y
AU  - Xia W
AU  - Du C
AU  - Xiong D
AU  - Song D
AU  - Shi Y
AU  - Yuan Z
AU  - Zheng Q
AU  - Jiang K
AU  - An X
AU  - Xue C
AU  - Huang J
AU  - Bi X
AU  - Chen M
AU  - Zhang J
AU  - Wang S
AU  - Hong R
PY  - 2024
JO  - NPJ breast cancer
DO  - 10.1038/s41523-024-00646-2
UR  - https://doi.org/10.1038/s41523-024-00646-2
ER  -

APA

D, C., F, X., Y, L., W, X., C, D., D, X., D, S., Y, S., Z, Y., Q, Z., K, J., X, A., C, X., J, H., X, B., M, C., J, Z., S, W., & R, H. (2024). Pyrotinib and trastuzumab plus palbociclib and fulvestrant in HR+/HER2+ breast cancer patients with brain metastasis.. NPJ breast cancer. https://doi.org/10.1038/s41523-024-00646-2

Source records

pubmed · retrieved 2026-09-25T17:48:23.554Z